Similarly, in epithelial ovarian cancer, miR-146a directly regulated the sensitivity of ovarian cancer cells to drug therapy and was also shown to target and reduce MyD88 expression, thus inhibiting NF-κB activation [123]. Here, MYD88 is linked to ovarian carcinoma.